Progress in the Treatment of Small Intestine Cancer.

Area of Science:

• Gastroenterology and Oncology
• Rare Gastrointestinal Malignancies

Background:

• Small intestine cancer is rare, comprising ~3% of GI malignancies.
• Common subtypes include adenocarcinoma, neuroendocrine tumors (NETs), and gastrointestinal stromal tumors (GISTs).
• Treatment strategies are often extrapolated from other cancers due to limited specific data.

Purpose of the Study:

• To review current management strategies for small intestine adenocarcinoma, NETs, and GISTs.
• To highlight recent advances and evidence for novel therapies.
• To provide an overview of treatment options based on histological subtype and disease stage.

Main Methods:

• Literature review of current evidence and recent clinical trials.
• Analysis of treatment efficacy in localized and advanced disease settings.
• Synthesis of data for adenocarcinoma, NETs, and GISTs.

Main Results:

• Surgery is the primary treatment for localized small intestine cancers.
• Chemotherapy and immunotherapy show potential in advanced small intestine adenocarcinoma.
• Somatostatin analogues are used for well-differentiated NETs; chemotherapy for poorly differentiated types.
• Imatinib targets KIT mutations in GISTs, with emerging options for resistant cases and immunotherapy.

Conclusions:

• Current treatment for small intestine cancers relies on limited evidence, necessitating further research.
• Advances in chemotherapy, immunotherapy, and targeted therapy are improving outcomes.
• Tailored treatment approaches based on tumor subtype and stage are crucial for optimizing patient survival.